Tag Archives: business

Hot Investor Mandate: Early-Stage VC Focused on Deeptech Innovation, Investing in Platform and Enabling Technologies from Pre-Seed to Series A

5 Aug

An early-stage venture capital firm focuses on deeptech innovation, with strategic emphasis on the Cleantech and Biotech sectors. The firm acknowledges the critical role that advanced materials play in promoting both planetary and human health. 

The firm typically invests from Pre-Seed through Series A, with average initial allocations around USD $500k and reserves for follow-on participation. Geographically, the firm targets North America and Asia, and is also open to public-ready companies or those preparing to go public. 

Within biotech, the firm seeks novel therapeutics and global health-enhancing medical breakthroughs. While broadly sector-agnostic, the firm prioritizes companies with a technology backbone. Preferred areas include: platform technologies, enabling tools for drug discovery & development, and synthetic biology 

The firm is indication-agnostic, though generally less interested in infectious diseases. 

There are no strict team or company prerequisites, though the firm prefers to have an investor presence on the board. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Canada-Based VC Invests in AI-Driven Technologies Including Medical Devices, Diagnostics, and Digital Health Across the Globe

5 Aug

A venture capital corporation is based in Canada with the government serving as a limited partner participates in Angel through Series A rounds, typically allocating CAD $100K to $200K for Angel rounds and CAD $500K to $1M for Pre-A and Series A rounds. It is open to co-investments and occasionally acts as a limited partner in other investment funds. The firm seeks innovative projects that align with the interests of its affiliated operating company, which specializes in immunology-based diagnostics. 

In addition to direct investments, the firm in-licenses intellectual property from universities and engages in joint ventures with other partners. With its own internal management and engineering team, the firm plays an active role in helping startups enter the market and commercialize their products. The firm is open to working with companies globally. 

Its core areas of interest include AI-driven digital health, medical devices, and diagnostics – particularly those involving antigen and antibody pairs. The firm favors companies that are nearing commercialization and can be integrated into its existing AI platform. A board seat is typically preferred in investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Get on Pharma’s Radar: What Big Companies Look for in Early-Stage Innovation

5 Aug

Live at RESI Boston – September 17 | Westin Copley Place 

By Momo Yamamoto, Senior Investor Research Analyst, LSN

For many early-stage life science companies, partnering with a major pharmaceutical firm can be a transformative milestone. Beyond capital, Big Pharma brings global reach, regulatory know-how, and commercialization muscle, opening doors that would otherwise be out of reach. But breaking through the noise and earning that opportunity requires more than a strong pitch deck.

The “Partnering with Big Pharma” panel at RESI Boston will offer a rare, inside look at how business development and licensing leaders identify and evaluate emerging innovation, including therapeutics and enabling technologies.

What Does Big Pharma Look For?

This 50-minute session will dive into the key criteria pharma decision-makers use to vet early-stage companies. From the strength of the data package and differentiation in a crowded landscape to alignment with therapeutic priorities and unmet need, the panel will shed light on how early is too early and when is just right to engage.

Attendees will also gain insight into how large pharma teams structure search & evaluation processes, how red flags are interpreted, and what signals strong partnership potential.

 Moderated by Jeremy Sohn, Managing Partner at P74 Ventures, this conversation brings together key voices shaping pharma’s external innovation strategy:

Jeremy-Sohn Hyelim-Cho Nikhil-Mutyal
Jeremy SohnManaging Partner
P74 Ventures
(Moderator)		 Hyelim ChoSenior Director, BD and Alliance Management
RayzeBio
(a Bristol Myers Squibb company)		 Nikhil MutyalHead of Search and Evaluation, Respiratory and Immunology
AstraZeneca
Armin-Rump Jenny-Wang
Armin RumpDirector of Global Business Development
Otsuka Pharmaceutical Co., Ltd.		 Jenny WangDirector, Search & Evaluation, Oncology
AbbVie

These leaders are actively scouting for high-impact innovations and will share how their organizations assess risk, potential, and fit in a rapidly evolving landscape. You will hear how shifting trends are reshaping pharma’s partnering approach, and what startups can do to stand out in a competitive environment.

Whether you are aiming for a strategic investment, licensing deal, or co-development partnership, this panel offers direct access to the minds shaping pharma’s innovation agenda. Founders, BD professionals, and investors alike will walk away with actionable insights into what it takes to get – and stay on – Big Pharma’s radar.

Register today and save with early bird rates.

Tags: , , , ,

China’s Biotech Boom: Innovation, Influence, and Rising Tensions 

5 Aug

By Sougato Das, President and COO, LSN

Sougato-Das

As 2025 progresses, China’s biotech and pharmaceutical sectors are not just growing—they’re reshaping the global industry landscape. With skyrocketing innovation, bold regulatory reform, and a deepening rivalry with the U.S., Chinese biotech firms are asserting their global presence at unprecedented speed. The GSK / Hengrui Pharma deal, involving a major collaboration potentially worth up to $12.5 billion, is the latest example. The deal focuses on developing up to a dozen drug candidates, primarily in respiratory diseases, immunology, infection, and oncology. GSK will pay Hengrui an upfront fee of $500 million, with the potential for significant milestone payments and royalties if the collaboration is successful. China will continue to play a major role in the worldwide biopharma ecosystem as…

China Emerges as a Global Drug Development Powerhouse

  • Record Licensing Activity: China-to-West drug licensing hit a record $41.5 billion in 2024, a staggering 66% jump from the previous year. Nearly 30% of global innovative drug assets now trace their origin to China.
  • Biotech Licensing Leadership: In 2024, 42% of all global biotech licensing deals over $50 million involved Chinese firms—up from 22% in 2023.

Drug Discovery Is Going East

  • Rapid Shift in Molecule Sourcing: One in three externally sourced molecules by global biopharma firms now comes from China—a dramatic rise from virtually none in 2019. Chinese biotech firms are lauded for their speed, efficiency, and low-cost synthesis of new compounds, positioning them as preferred partners for drug discovery.

Clinical Trials and Regulatory Momentum increases in China

  • China’s Clinical Surge: In 2023, nearly 28% of global clinical trial sponsorships originated from China—up from just 4% a decade ago. Registrations alone rose by 26% last year.
  • Faster to Market: Thanks to reforms by China’s National Medical Products Administration (NMPA), investigational new drugs can now be approved for human testing in just 60 working days.
  • FDA Recognition: Chinese trials are increasingly qualifying for FDA priority pathways, challenging the traditional dominance of U.S.-based clinical development.

China is at the Cutting Edge of Gene Editing

  • CRISPR Leadership: Chinese startups like YolTech (in vivo CRISPR therapy) and Huidagene (brain-targeted CRISPR trials) are leading in next-gen gene editing.
  • Global Recognition: According to Goldman Sachs, China is at the forefront of CRISPR and CAR-T research.

Tensions and Regulatory Hurdles deepen with the US

  • Geopolitical Pressure: Proposed U.S. legislation—the BIOSECURE Act—would prohibit drugmakers with federal contracts from using Chinese firms like WuXi AppTec and WuXi Biologics after 2032. This could disrupt global supply chains and complicate R&D strategies for U.S. companies.
  • Scientific Chilling Effect: Fears of increased scrutiny are causing some Chinese and Chinese-American researchers to avoid applying for NIH grants, impacting U.S.-China scientific collaboration.
  • Investment Headwinds: Despite innovation, venture capital investment in Chinese biotech has declined due to geopolitical uncertainty.

Cross-Border Deals Multiply

  • Western Biopharma Engagement: U.S. and European firms are actively pursuing licensing and partnership deals with Chinese biotechs—particularly in ADC and bispecific antibody platforms, expanding beyond oncology.
  • Investor Sentiment Splits: Some U.S. investors advocate for protectionist strategies, while others see China’s rise as an opportunity for strategic alignment and access to novel therapies.

What Does All This Means for the Industry>

China is no longer simply a “fast follower” in biotech. It’s now an originator of breakthrough science, shaping the future of global drug development, even as geopolitical tensions threaten to redraw the map of international collaboration.

As global biopharma leaders and investors reassess their strategies, one thing is clear: ignoring China’s biotech ascent is no longer an option.

Tags: , , , , , , , , , , ,

Partnering Launches August 11 for RESI Boston September 

5 Aug

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Partnering at RESI Boston 2025 is set to launch next Monday, August 11. The RESI series have consistently been the largest early-stage life science partnering events, in terms of investor attendance, and with 400+ investors/ strategic licensing partners expected to participate in September, RESI Boston September will be a turnkey event for entrepreneurs who are looking to raise capital.

With both in person and virtual registration options, as well as a handful of remaining spots open in our Innovator’s Pitch Challenge, companies can take advantage of Life Science Nation (LSN)’s unique partnering system to set meetings directly with global investors/ in-licensors who are a fit for their product’s sector, indication, stage of development and geographic region.

Companies looking to register can do so before this Friday, August 8th to take advantage of our Early Bird Pricing discounts. LSN will also be hosting a free partnering tutorial webinar on August 18th to help companies maximize the number of secured meetings.

Tags: , , , , , , , , , , ,

JPM 2026: Partnering, Event/Reception Space Available at RESI JPM

29 Jul

Host your event. Launch your brand. Meet your partners.

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation (LSN) has secured a 20,000 square foot (1900 square meters) space at the Marriott Marquis in Union Square in the heart of JPM Week 2026. This premium venue will serve as the headquarters for the Redefining Every Stage of Investment (RESI) conference on Monday and Tuesday, January 12 and 13—but we’re opening the doors Sunday, January 11 for groups looking to host their own event in the center of the action.

We’re inviting economic development agencies, global trade organizations, venture groups, and industry associations to partner with LSN or book standalone time in this flagship location.

The Space

  • 20,000 square feet of meeting and activation space
  • 4 fully equipped conference rooms (2400 square feet/220 square meters), good for theater-style seating for presentations or a small networking event
  • 90+ RESI-style partnering tables
  • Full-service meeting logistics support available

This space is ideal for:

  • Networking receptions, investor briefings, and pitch showcases
  • Country or region-specific innovation days
  • Workshops, roundtables, or startup presentations
  • Private investor or industry partner meetings

Flexible Integration Options

  • January 11 (Sunday): Available for standalone programs, private events, or pre-RESI activities
  • January 12 and 13 (Monday and Tuesday): Integrate into the RESI JPM program, gain access to hundreds of global investors, and use the space to host partner meetings or specialized tracks within the RESI ecosystem

LSN is already in discussion with a range of organizations, including tech hubs, economic development agencies, service providers, and nonprofit patient groups who are seeking affordable options for hosting events and partnering at JPM.

Why Co-Locate with LSN During JPM?

  • Prime Union Square location just steps from the major hotel hubs and investor meetings
  • Built-in foot traffic and visibility from RESI attendees, investors, and partners
  • Flexible use of infrastructure and logistics support from the LSN team
  • Branding and signage opportunities throughout the venue
  • Streamlined meeting scheduling and visibility if integrated into the RESI partnering platform

Make It Yours

Whether you’re looking to host a private country reception, a thematic track inside RESI, or a custom event that aligns with your mission, the space is move-in ready and centrally located. We can help with meeting set-up, agenda development, signage, staffing, registration flow, and more.

Interested in booking or learning more?
Contact salescore@lifesciencenation.com to discuss options, availability, and pricing.

Let’s create a high-impact presence for your organization at the most important week in global life sciences.

Tags: , , , , , , , , , ,

Beyond the Pitch: Why Life Science Startups Fail and How BD Assist Closes the Execution Gap

29 Jul

A deeper dive into what really moves the needle for early-stage fundraising

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022A few weeks ago, we introduced BD Assist, Life Science Nation’s full-service global partnering campaign designed to take the burden of business development off the founder’s desk and get real investor meetings on the calendar. The response from experienced founders was immediate.

Here is the truth: BD Assist is not for first-time founders who are still learning the ropes. It is built for the second, third, or fourth time scientist-entrepreneur. The one who already knows how hard this game is, who is tired of chasing down investor meetings between running a company, and who understands the real value of having a professional team help run the global campaign infrastructure.

If you missed the original rollout, you can view the BD Assist overview deck here for a clear breakdown of how the system works.

Why Execution Still Kills Good Science
Even with scientific momentum and breakthrough data, more than 90 percent of early-stage life science companies still fail. Not because the science is not good, but because most founders never make it through the long middle: the grind of targeting, messaging, outreach, and follow-up. They do not reach enough of the right capital investors and licensing partners. They do not have a CRM that tracks investor touchpoints. They do not have time to build and run a campaign while also managing a preclinical program or preparing for the next financing round.

BD Assist exists to fill that gap. To build the campaign, manage the outreach, and hand the founder a pipeline of matched meetings so they can do what they do best. Show up, pitch hard, and close deals.

What BD Assist Actually Does
At its core, BD Assist is a global investor and partner matching engine, backed by a professional services team that handles the heavy lifting. It is not just coaching or strategy. It is a full campaign execution.

  • Matching 600 to 800 capital investors and licensing partners based on stage, product, and deal profile
  • Direct introductions, meeting scheduling, and post-meeting follow-up across LSN’s global network and the RESI conference series
  • CRM setup and outreach execution so you can track progress, engagement, and pipeline movement
  • Messaging and content coaching to sharpen your story across decks, summaries, and calls
  • Strategic support from executive coaches who have helped close hundreds of investor and licensing deals

Need to See the System
Watch our Investor Database demo to understand how we match based on fit, not just category.
Take our free campaign readiness assessment to see if you are ready to scale your outreach.
Or sign up for the next RESI Conference to meet matched investors and pitch in the Innovator’s Pitch Challenge.

This BD Assist Model Works
Our partnership with the Brisbane Economic Development Agency proved it. Over the course of two years, 90% of companies raised more than $ 110 million. Why? Because we did not just teach them how to pitch. We provided them with a comprehensive global campaign system and assisted in its implementation. Click here to read the case study article.

Who is BD Assist Really For
BD Assist is for scientist-entrepreneurs who are already in motion. Founders who have been through a raise know how time-consuming investor engagement really is and are ready to hand off the execution to a trusted team.

Your job is to show up to meetings and move the needle. Our job is to fill the calendar with the right meetings, every week, for the next 9 to 18 months.

Want to Get Started
Contact resi@lifesciencenation.com to learn more.

Because in life sciences, science gets you noticed. Execution gets you funded.

Tags: , , , , , , ,

← Older Entries
Newer Entries →